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Abstract
Background: It has been shown that selenium-binding protein 1 (SBP1) is significantly downregulated in different human
cancers. Its regulation and function have not yet been established.
Methodology and Principal Findings: We show that the SBP1 promoter is hypermethylated in colon cancer tissues and
human colon cancer cells. Treatment with 59-Aza-29-deoxycytidine leads to demethylation of the SBP1 promoter and to an
increase of SBP1 promoter activity, rescues SBP1 mRNA and protein expression in human colon cancer cells. Additionally,
overexpression of SBP1 sensitizes colon cancer cells to H2O2-induced apoptosis, inhibits cancer cell migration in vitro and
inhibits tumor growth in nude mice.
Conclusion and Significance: These data demonstrate that SBP1 has tumor suppressor functions that are inhibited in
colorectal cancer through epigenetic silencing.
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Introduction
Selenium binding protein 1 (SBP1) is a 56-KDa protein which is
expressed invariouscelltypes,including the heart,liver,kidney,lung
and intestine. Human SBP1 was first cloned in 1997 [1] and has
been suggested to mediate the intracellular transport of selenium [2].
SBP1 has also been proposed to serve as a marker in colonic cell
differentiation and recently, SBP1 has been shown to be a target of
the hypoxia-inducible factor-1 alpha (HIF1a) [3] and to directly
interact with von Hippel-Lindau protein (pVHL) which may play a
role in the proteasomal degradation pathway in a selenium
dependent manner [4]. SBP1 has been shown to be decreased in
various epithelial cancers, including prostate [5], stomach [6],
ovaries[7],lungs[8]andcolorectalcancers[9,10].Furthermore,low
expression levels of SBP1 in colorectal cancer were associated with
poor prognosis [9,10]. Similar results have been observed in lung
adenocarcinomas [8] and pleural mesotheliomas [11]. Based on
these studies it has been proposed that SBP1 may play a critical role
in regulating cancer growth and progression. However, the role of
SBP1 in these pathways has not been elucidated.
Epigenetic alterations cause gene silencing, leading to loss of
gene expression and function. Two commonly mechanisms have
been observed: histone modification and DNA methylation. The
latter occurs at cytosine residues in cytosine-guanine (CpG)
sequences. Methylation of CpG islands at the promoter is often
an early event in tumor progression and is a common mechanism
of gene silencing in cancers, occurring in more than 60% of tumor
suppressors [12–14].
SBP1 has been identified to have 2 CpG islands in its 59-
untranslated region, one of which being close enough to have an
impact on the SBP1 promoter regulation (2402 to 2613). It is
therefore possible that the SBP1 promoter, in tumors with low
expression levels of SBP1, may be methylated. Indeed, our data
reveal that the SBP1 promoter is hypermethylated in human colon
cancer tissues and in human colon cancer cell line HCT116, but a
general demethylating agent 59-Aza-29-Deoxycytidine (or 59-aza-
decitabine, DAC) restores SBP1 mRNA and protein expression by
demethylating the SBP1 promoter region and increasing SBP1
promoter activity. We furthermore provide the first evidence to
show that SBP1 has anti-cancer functions - overexpression of
SBP1 in HCT116 cells induces H2O2 -mediated apoptosis, inhibits
cell migration in vitro and inhibits tumor growth in nude mice.
Materials and Methods
Cell Culture, Human Colon Cancer Tissues and Reagents
Human colon cancer cell line HCT116 was cultured in
McCoy’s 5A media supplemented with 10% FBS, 1% anitbiotic-
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incubator with 5% CO2. Human colon cancer cell lines LS174T,
Caco2, HT29 and SW480 were maintained in Minimal Essential
Medium (MEM) and maintained under the same conditions as
HCT116 cells. Human colon cancer tissues and matched normal
tissues have been used by our laboratory recently [10]. For H2O2
treatment, cells at 80% confluence were treated with 0.3 mM
H2O2 for 24 hours. For demethylation studies, cells were treated
with 10 and 30 mMo f5 9-Aza-29-Deoxycytidine (DAC) for 72 or
96 h (Sigma, St. Louis, MO).
Plasmids Construction
Human SBP1 cDNA was amplified and subcloned into pIRES2
vectors (Clontech, Mountain View, CA) (pIRES2-SBP1) using
XhoI and BamHI restriction enzyme sites. The following primers
were used: forward: 59-ATCTCGAGCTATGGCTACGAAAT-
GTGGGAAT-39 and reverse: 59-ATGGATCCTCAAATCCA-
GATGTCAGAGCTAC-39. To generate HA-SBP1 plasmid, hu-
man SBP1 cDNA was amplified and subcloned into HA-tagged
pcDNA3.1 vector (pHA) (Invitrogen, Carlsbad, CA) using XbaI
and XhoI restriction sites. The following primers were used:
forward: 59-ATCTCGAGATGGCTAC GAAATGTGGGAA-
TT-39 and reverse: 59-ATTCTAGATCAAATCCA GATGTCA-
GAGCTAC-39. For luciferase assays full length of the SBP1
promoter (22572 to +1) (pGL4-SBP1) was cloned into the pGL4
vector (Promega Corporation, Madison, WI) using XhoI and
HindIII restriction sites. The following primers were used: forward
59-ATCTCGAGCCCATACATACCA AGCAA -39 and reverse
59-TCAAGCTTCGGGTTTGCTGTGCTGGTGTC-3. Accu-
racy of all plasmids was confirmed via sequencing.
Transfection
Transient transfection of HCT116 cells with pHA-SBP1 or
pHA vector control was performed via Lipofectamine 2000
(Invitrogen, Carlsbad, CA). 24–48 h after transfection, cells were
subject to different assays. For stable transfection, HCT116 cells
were transfected with pIRES2-SBP1 or pIRES2 (empty vector)
alone via Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Stably
transfected cells were selected with G418.
Immunoblotting
For immunoblotting, cells were collected 72 hours after treat-
ment.Cellswerelysedusing1xRIPAbuffer(UpstateBiotechnology,
Lake Placid, NY)containinga proteaseinhibitorcocktail (Sigma, St.
Louis, MO). After cell lysis, 30 mg of protein was loaded on a 10%
SDS gel followed by transfer to PVDF membrane. Monoclonal
antibody against SBP1 was purchased from MBL.
International Corporation (Watertown, MA; 1:1000), the
antibody against b-actin was purchased from (Sigma, St. Louis,
MO; 1:10000). Secondary anti-mouse antibody was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA; 1:3000). The
detected signals were visualized by an enhanced chemilumines-
cence reaction system, as recommended by the manufacturer
(ECL-Plus, Amersham, Piscataway, NJ).
Methylation-Specific PCR (MS-PCR)
HCT116 cells were treated with or without DAC for 96 hours
followed by DNA purification (DNeasy, Qiagen, Valencia, CA).
Purified DNA was then converted using the EZ-DNA bisulifide
conversion kit from Zymo Research (Orange, CA), which converts
cytosine residues to uracil, but does not affect 5-methylcytosine, thus
allowing one to identify methylated sequences in the DNA by
subsequent MS-PCR. For MS-PCR, methylation and unmethylation
specific primers (designed by methylation identification software) [15]
complementary to the CpG island spanning 2463 to 2673 of the 59
untranslated region were used. PCR was then performed using equal
amounts of DNA and the iTaq
TM DNA ploymerase (Bio-Rad,
Hercules, CA) under the following conditions: initial polymerase
activation at 95uCf o r5m i n u t e s ,9 5 uCf o r4 5s e c ,5 3 uC( m e t h y l a t e d
product) or 50uC (unmethylated product) for 45 sec followed by
elongation at 72uC for 45 minutes. After 35 cycles, the reaction was
furthermore incubated at 72uC for 10 minutes. The total PCR
product was then run on a 2% agarose gel. Accuracy of product was
determined via sequencing.
Luciferase Assay
HCT116 cells were transfected with a pGL4 empty vector
or pGL4-SBP1 plasmid which contains the full length SBP1
promoter. Renilla was co-transfected as an internal control. 24 h
after transfection, cells were treated with PBS or 59-Aza-29-
Deoxycytidine for 72 h. The dual luciferase activity kit (Promega,
Madison, WI) was used in combination with a luminometer to
measure luciferase activity of treated cells according to the
manufacturers’ protocol.
Proliferation, Apoptosis and Migration Analysis
Cell proliferation was analyzed by MTS assay according to the
manufacture’s protocol (Promega, Madison, WI). To detect apopto-
sis, stably transfected HCT116-SBP1 or vector control cells were
harvested and fixed with 70% ethanol followed by propidium iodide
staining. Cells were then counted by flow cytometry (FACScan, BD
Biosciences, San Jose, CA). Cell migration was detected using a
transwell plate (Corning, Lowell, MA) followed by DAPI staining.
Xenografts
1610
6 HCT116 cells stably expressing pIRES2-SBP1 or
pIRES2 vector were injected subcutaneously into the flank of




Laboratory, NY) (5 mice per group). The animals were maintained
in a pathogen-free barrier facility at the University of Illinois at
Chicago Biological Resources Laboratory, and closely monitored
by animal facility staff. Four weeks after injection, tumors were
isolated and the weight (gm) and volume (mm
3) of tumors were
determined. Total RNA was isolated from the tumor, quantitative
real-time RT-PCR were performed, as described in our recent
report [10], to validate SBP1 constitutive expression in the xeno-
grafts. All procedures were conducted according to the Animal
Care and Use guideline and were approved by the University of
Illinois at Chicago Animal Care Committee.
Results and Discussion
SBP1 Promoter Was Highly Methylated in Human Colon
Cancer Tissues
We recently reported that SBP1 protein and mRNA expression
was dramatically reduced in human colorectal cancer [10], as well
as in other types of cancers. To elucidate the reason of gene
expression reduction, we isolated targeted human colon cancer
cells and matched normal colonic epithelial cells from colorectal
cancer patients with low tumor-SBP1 protein and mRNA
expression [10] for SBP1 promoter methylation analysis. Surpris-
ingly, we found indeed that the SBP1 promoter was higher
methylated in these tumors compared to their adjacent normal
mucosa (Fig. 1A). Although higher sample volumes are needed to
signify these results, these data clearly demonstrate that SBP1
promoter methylation may be one of the mechanisms responsible
for SBP1 downregulation in human colon cancers.
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To validate SBP1 promoter methylation and the SBP1 gene
expression, human colon cancer cell lines were employed. First, we
found various SBP1 protein levels in several cell lines analyzed by
Western blotting (Fig. 1B). We then initially selected two cell lines
for methylation analysis: LST174T cells which have highest level of
SBP1 and HCT116 cells which have an undetectable SBP1 protein
expression. As shown in figure 1C, SBP1 promoter was highly
methylated in HCT116 cells, while it was mostly unmethylated in
LS174T cells. Subsequent sequencing of excised methylated and
unmethylated bands confirmed accuracy of the methylation pattern
seen in these two cell lines and did not reveal any obvious mutations
in the promoter region of SBP1. We also examined SBP1 promoter
methylation status in SW480, Caco-2 and HT-29 cells, which have
low, moderate and high expression levels of SBP1 protein,
respectively (Fig. 1B). Consistent with SBP1 protein expression,
the SBP1 promoter was highly methylated in SW480 cells,
moderately methylated in Caco-2 cells and methylated to a lesser
extent in HT-29 cells (Fig. 1C). We next treated HCT116 cells with
the general demethylating agent 59-Aza-29-Deoxycytidine to
determine whether the hypermethylated SBP1 promoter could be
demethylated. We found that treatment of HCT116 cells with
30 mM of DAC for 96 h decreased SBP1promotermethylation and
increased SBP1 promoter unmethylation, compared to the PBS
treatment control (Fig. 1D). This suggests that the SBP1 promoter is
Figure 1. SBP1 promoter was hypermethylated in human cancer tissues and colon cancer cell lines, which silenced gene expression
and was revered by 5-Aza-29-Deoxycytidine (DAC). A, SBP1 promoter was highly methylated in human colon cancer tissues. Genomic DNA
from adjacent normal (N) and adenocarcinoma (T) tissue was isolated, converted and amplified for human SBP1 promoter using MS-PCR. # indicated
different patients. Unmethylated (U) and methylated (M) bands were detected by DNA separation on 2% agarose gels with ethidium bromide. B,
Western blotting analysis showed various expression of SBP1 in human colon cancer cell lines; HCT116 cells with stable transfection of SBP1
overexpressing plasmid was used as positive control. C, SBP1 promoter was hypermethylated in HCT116 cells. Genomic DNA from LS174T, HCT116,
SW480, Caco-2 and HT-29 colon cancer cells was isolated, converted and amplified via MS-PCR for human SBP1 promoter followed by gel separation
of total DNA on 2% agarose gels (U, unmethylated DNA; M, methylated DNA). D, DAC reversed SBP1 promoter methylation in HCT116 cells. DNA from
HCT116 cells treated with 30 mM of DAC for 96 h was isolated and separated on 2% agarose gels after conversion and MS-PCR. E, Luciferase assay
showed that DAC increased SBP1 promoter luciferase activity of HCT116 cells with transfection of a vector containing the full length promoter of
SBP1 and with a treatment of 30 mM DAC or PBS for 72 hours. pGL4 vector and Renilla was co-transfected as controls (* p,0.01, compared to PBS).
F, DAC restored SBP1 protein expression in HCT116 cells with DAC treatment for 72 h, analyzed by Western blotting. G. SBP1 mRNA was restored by
DAC in HCT116 cells (* p,0.01, compared to PBS). Each experiment was performed at least 3 times.
doi:10.1371/journal.pone.0007774.g001
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promoter hypermethylation silences SBP1 expression in HCT116
human colon cancer cells.
SBP1 Promoter Demethylation Increased SBP1 Promoter
Activity and Rescued SBP1 Expression
Our data demonstrate that the SBP1 promoter is hypermethy-
lated and that the demethylating agent DAC could reverse this
case. It is therefore important to elucidate whether promoter
demethylation could subsequently increase SBP1 promoter activity
and SBP1 mRNA and protein expression. First, we transfected
HCT116 cells with a luciferase plasmid containing the full length
SBP1 promoter region (pGL4-SBP1) and treated the cells with
30 mM DAC for 72 h to test if DAC treatment increases promoter
activity, and found that DAC indeed increased SBP1 promoter
activity by 3 fold (Fig. 1E). Consistently, HCT116 cells treated
Figure 2. SBP1 had tumor suppressive functions. A, HCT116 cells transfected with HA-SBP1 had an increased sensitivity to H2O2 by MTS
proliferation assay compared to the empty vector (HA). The cells were treated with H2O2 for 24 hours. B, HCT116 cells transfected with HA-SBP1
increased H2O2-induced apoptosis by Flow cytometry analysis. Cells were treated with 0.3 mM of H2O2 for 24 hours. Boxes indicate apoptotic cells
(sub-G1). C, SBP1 inhibited cancer cell migration: cell migration of SBP1 overexpressing HCT116 cells and HA-control cells was assessed via transwell
chambers. Migrated cells were detected with DAPI staining.
doi:10.1371/journal.pone.0007774.g002
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protein expression in a dose-dependent manner (Fig. 1F).
Additionally, DAC treatment increased SBP1 mRNA levels by
50 folds for 72 h treatment and 89 folds for 96 h treatment in
HCT116 cells (Fig. 1G). Although other mechanisms for the
regulation of SBP1 can not be ruled out, these experiments suggest
that SBP1 expression in human colon cancer cells is silenced in
part by its promoter methylation and that SBP1 expression can be
rescued by demethylating the promoter region.
SBP1 Inhibits Cell Proliferation, Increases Apoptosis and
Inhibits Cell Migration
SBP1 has been shown to be involved in the intracellular transport
of selenium [2] and to serve as a marker in colonic cell
differentiation [10]. SBP1 has also been shown to be decreased in
different human cancers. However, its functions in cancers have not
yet been defined. Therefore, we wanted to identify the functions
SBP1 might have in human colon cancer cells. One hallmark of
cancer is uncontrolled cell proliferation. To test if SBP1 might
influence cell proliferation, HCT116 cells overexpressing SBP1
were treated with different concentrations of H2O2 and cell
proliferation was analyzed via an MTS assay (Promega, Madison,
WI). Although treatment of cells with 0.2 mM H2O2 itself inhibited
cell proliferation in HCT116 cells, it can be appreciated that SBP1
overexpression sensitized HCT116 cells to H2O2-induced growth
inhibitionat lower concentrations (,0.2 mM), indicating that SBP1
might play a role in cell cycle regulation (Fig. 2A). FACS analysis
revealed that SBP1 overexpression led to an increase of apoptotic
cell death (sub-G1 fraction) when cells were treated with H2O2
(Fig. 2B). Moreover, overexpression of SBP1 in HCT116 cells
inhibited human colon cancer cell migration (Fig. 2C). These
experiments suggest that SBP1 may have some tumor suppressive
functions in human colon cancer cells.
SBP1 Attenuated Colorectal Cancer Cell Growth in NIH-III
Nude Mice
To test if SBP1 has anti-tumor activities in vivo, we performed
xenograft experiments in NIH-III nude mice using HCT116 cells
which either stably overexpress SBP1 (pIRES2-SBP1) or a control
vector(pIRES2). Fourweeks aftercancer cell injection,tumors were
isolated and tumor volume and weight was determined. SBP1
expression in explanted tumors derived from SBP1 overexpressing
HCT116 cells was confirmed via RT-PCR showing 607-fold
increase at mRNA level. Consistent with in vitro data, mice injected
with SBP1 overexpressing HCT116 cells had a significantly smaller
tumor volume (Fig. 3A) and tumor weight (Fig. 3B) than the mice
injected with control cells, indicating that SBP1 has tumor
suppressive functions in vivo as well.
Taken above,we provide the first evidencethat SBP1 promoter is
hypermethylated in human colorectal cancer, and that demethyl-
ation via DAC increases SBP1 promoter activity as well as rescuing
mRNA and protein expression (Fig. 1). Gene silencing is a common
mechanism found in many human cancers to inhibit tumor
suppressor expression. Our data show that the SBP1 promoter is
highly methylated in tumor tissues of colorectal cancer patients,
indicating that SBP1 expression in colon cancer is in part controlled
through gene silencing. It is critical to investigate whether SBP1
gene silencing is a common mechanism to reduce SBP1 expression
in other types of cancer in which SBP1 has been shown to be
downregulated. Moreover, due to decreased expression of SBP1 in
human cancers, SBP1 hasbeen suggested to havetumorsuppressive
activities. We believe that we are the first ones to provide evidence
thatthismayindeedbetrue,intermsofthatoverexpressionofSBP1
in HCT116 cells suppressed cell proliferation, increased apoptotic
cell death and decreased cell migration in vitro (Fig. 2), and inhibited
tumor growth in vivo (Fig. 3). However, the exact mechanisms of
SBP1 regulation and anti-cancer action remain unknown and need
further investigation. In fact, it is currently being investigated in our
laboratory. Understanding the regulation and mechanisms of SBP1
tumor suppressor functions will have a great impact in revealing the
molecular mechanism of carcinogenesis and in developing more
effective chemoprevention and chemotherapies for human malig-
nant diseases.
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